Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine [version 1; peer review: 2 approved]

Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine [version 1; peer review: 2 approved]

Hydroxyurea (HU) alone has the potential to prevent one out of every three deaths due to sickle cell disease (SCD) and almost all forms of disabilities caused by SCD. However, in Tanzania, only one out of every six registered SCD patients in the SPARCO-Tanzania Sickle Cell Cohort use HU. We conducte...

Full description

Bibliographic Details
Main Authors: Irene Kida, Paschal Rugajo, Hamu Mlyuka, Nathanael Sirili, Julie Makani, Agnes Jonathan, Lulu Chirande, Hilda Tutuba, Manase Kilonzi, Emmanuel Balandya
Format: Article
Language:English
Published: F1000 Research Ltd 2022-05-01
Series:F1000Research
Subjects:
Hydroxyurea
Quality of Life
Sickle Cell Disease and Tanzania
eng
Online Access:https://f1000research.com/articles/11-554/v1

Internet

https://f1000research.com/articles/11-554/v1

Similar Items